Planned Phase 2 Trial of Oral Parkinson’s Therapy Takes Step Forward – Parkinson’s News Today

A planned Phase 2 clinical trial evaluating ANVS401, Annovis Bio‘s lead investigational therapy for people in the early stages of Alzheimer’s and Parkinson’s disease, has received approval from a central institutional review board (IRB).

An IRB is an administrative body responsible for protecting the rights and welfare of human research subjects participating in clinical trials. Among its duties, the IRB reviews a trial’s proposed design and purpose to ensure they are up to ethical standards.

Click here to read full article

Font Resize